142 related articles for article (PubMed ID: 9021281)
1. The short-term impact of Botox injections on speech disability in adductor spasmodic dysphonia.
Epstein R; Stygall J; Newman S
Disabil Rehabil; 1997 Jan; 19(1):20-5. PubMed ID: 9021281
[TBL] [Abstract][Full Text] [Related]
2. Botox treatment in adductor spasmodic dysphonia: a meta-analysis.
Boutsen F; Cannito MP; Taylor M; Bender B
J Speech Lang Hear Res; 2002 Jun; 45(3):469-81. PubMed ID: 12069000
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section.
Sulica L; Blitzer A; Brin MF; Stewart CF
Ann Otol Rhinol Laryngol; 2003 Jun; 112(6):499-505. PubMed ID: 12834116
[TBL] [Abstract][Full Text] [Related]
4. The effect of patient factors on response outcomes to Botox treatment of spasmodic dysphonia.
Lundy DS; Lu FL; Casiano RR; Xue JW
J Voice; 1998 Dec; 12(4):460-6. PubMed ID: 9988033
[TBL] [Abstract][Full Text] [Related]
5. Interarytenoid muscle botox injection for treatment of adductor spasmodic dysphonia with vocal tremor.
Kendall KA; Leonard RJ
J Voice; 2011 Jan; 25(1):114-9. PubMed ID: 20137891
[TBL] [Abstract][Full Text] [Related]
6. Surgery or botulinum toxin for adductor spasmodic dysphonia: a comparative study.
Mendelsohn AH; Berke GS
Ann Otol Rhinol Laryngol; 2012 Apr; 121(4):231-8. PubMed ID: 22606926
[TBL] [Abstract][Full Text] [Related]
7. Adductor muscle activity abnormalities in abductor spasmodic dysphonia.
Cyrus CB; Bielamowicz S; Evans FJ; Ludlow CL
Otolaryngol Head Neck Surg; 2001 Jan; 124(1):23-30. PubMed ID: 11228447
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia.
Morzaria S; Damrose EJ
J Voice; 2012 May; 26(3):378-80. PubMed ID: 20951552
[TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin treatment of false vocal folds in adductor spasmodic dysphonia: Functional outcomes.
Simpson CB; Lee CT; Hatcher JL; Michalek J
Laryngoscope; 2016 Jan; 126(1):118-21. PubMed ID: 26467807
[TBL] [Abstract][Full Text] [Related]
10. Alternating unilateral botulinum toxin type A (BOTOX) injections for spasmodic dysphonia.
Koriwchak MJ; Netterville JL; Snowden T; Courey M; Ossoff RH
Laryngoscope; 1996 Dec; 106(12 Pt 1):1476-81. PubMed ID: 8948606
[TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients.
Blitzer A; Brin MF; Stewart CF
Laryngoscope; 1998 Oct; 108(10):1435-41. PubMed ID: 9778279
[TBL] [Abstract][Full Text] [Related]
12. The psychosocial consequences of BOTOX injections for spasmodic dysphonia: a qualitative study of patients' experiences.
Baylor CR; Yorkston KM; Eadie TL; Maronian NC
J Voice; 2007 Mar; 21(2):231-47. PubMed ID: 16564675
[TBL] [Abstract][Full Text] [Related]
13. Adductor spasmodic dysphonia: Botulinum toxin a injections or laser thyroarytenoid myoneurectomy? A comparison from the patient perspective.
Schuering JHC; Heijnen BJ; Sjögren EV; Langeveld APM
Laryngoscope; 2020 Mar; 130(3):741-746. PubMed ID: 31169922
[TBL] [Abstract][Full Text] [Related]
14. Unilateral versus bilateral injections of botulinum toxin in patients with adductor spasmodic dysphonia.
Bielamowicz S; Stager SV; Badillo A; Godlewski A
J Voice; 2002 Mar; 16(1):117-23. PubMed ID: 12002878
[TBL] [Abstract][Full Text] [Related]
15. Supraglottal injection of botulinum toxin type A in adductor type spasmodic dysphonia with both intrinsic and extrinsic hyperfunction.
Schönweiler R; Wohlfarth K; Dengler R; Ptok M
Laryngoscope; 1998 Jan; 108(1 Pt 1):55-63. PubMed ID: 9432068
[TBL] [Abstract][Full Text] [Related]
16. Tridimensional assessment of adductor spasmodic dysphonia pre- and post-treatment with Botulinum toxin.
Dejonckere PH; Neumann KJ; Moerman MB; Martens JP; Giordano A; Manfredi C
Eur Arch Otorhinolaryngol; 2012 Apr; 269(4):1195-203. PubMed ID: 22210475
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of voice quality in adductor spasmodic dysphonia before and after botulinum toxin treatment.
Langeveld TP; van Rossum M; Houtman EH; Zwinderman AH; Briaire JJ; Baatenburg de Jong RJ
Ann Otol Rhinol Laryngol; 2001 Jul; 110(7 Pt 1):627-34. PubMed ID: 11465821
[TBL] [Abstract][Full Text] [Related]
18. Acoustic variations in reading produced by speakers with spasmodic dysphonia pre-botox injection and within early stages of post-botox injection.
Sapienza CM; Cannito MP; Murry T; Branski R; Woodson G
J Speech Lang Hear Res; 2002 Oct; 45(5):830-43. PubMed ID: 12381042
[TBL] [Abstract][Full Text] [Related]
19. Gender differences in onabotulinum toxin A dosing for adductor spasmodic dysphonia.
Lerner MZ; Lerner BA; Patel AA; Blitzer A
Laryngoscope; 2017 May; 127(5):1131-1134. PubMed ID: 27633917
[TBL] [Abstract][Full Text] [Related]
20. Effect of Botulinum Toxin and Surgery among Spasmodic Dysphonia Patients.
van Esch BF; Wegner I; Stegeman I; Grolman W
Otolaryngol Head Neck Surg; 2017 Feb; 156(2):238-254. PubMed ID: 27803079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
